Pomalyst plus Velcade with dexamethasone improves survival outcomes for patients with relapsed/refractory multiple myeloma, according to a phase 3 trial. The treatment combination of Pomalyst ...
Among patients who were newly diagnosed with multiple myeloma, Kyprolis (carfilzomib) plus Revlimid (lenalidomide) and dexamethasone (KRd) was associated with improvements in progression-free survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback